These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11986248)

  • 1. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia.
    Tefferi A; Mesa RA; Gray LA; Steensma DP; Camoriano JK; Elliott MA; Pardanani A; Ansell SM; Call TG; Colon-Otero G; Schroeder G; Hanson CA; Dewald GW; Kaufmann SH
    Blood; 2002 May; 99(10):3854-6. PubMed ID: 11986248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
    Tsimberidou AM; Colburn DE; Welch MA; Cortes JE; Verstovsek S; O'Brien SM; Albitar M; Kantarjian HM; Giles FJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):229-34. PubMed ID: 12783207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
    Bastie JN; Garcia I; Terré C; Cross NC; Mahon FX; Castaigne S
    Haematologica; 2004 Oct; 89(10):1263-4. PubMed ID: 15477214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
    Hernández-Boluda JC; Cervantes F
    Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib and ruxolitinib association: first experience in two patients.
    Iurlo A; Gianelli U; Rapezzi D; Cattaneo D; Fermo E; Binda F; Santambrogio E; Bucelli C; Cortelezzi A
    Haematologica; 2014 Jun; 99(6):e76-7. PubMed ID: 24633869
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
    Ikuta K; Torimoto Y; Jimbo J; Inamura J; Shindo M; Sato K; Tokusashi Y; Miyokawa N; Kohgo Y
    Int J Hematol; 2005 Nov; 82(4):343-6. PubMed ID: 16298828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
    Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
    Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
    Cortes J; Ault P; Koller C; Thomas D; Ferrajoli A; Wierda W; Rios MB; Letvak L; Kaled ES; Kantarjian H
    Blood; 2003 Jun; 101(12):4714-6. PubMed ID: 12595304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?
    Druker BJ
    J Natl Cancer Inst; 2002 Nov; 94(22):1660-1. PubMed ID: 12441314
    [No Abstract]   [Full Text] [Related]  

  • 18. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.
    Bauer S; Hagen V; Pielken HJ; Bojko P; Seeber S; Schütte J
    Anticancer Drugs; 2002 Sep; 13(8):847-9. PubMed ID: 12394270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate.
    Yalamanchili K; Liu D; Seiter K
    Leukemia; 2007 Mar; 21(3):577-8. PubMed ID: 17230224
    [No Abstract]   [Full Text] [Related]  

  • 20. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.
    Feldman E; Najfeld V; Schuster M; Roboz G; Chadburn A; Silver RT
    Exp Hematol; 2003 Aug; 31(8):702-7. PubMed ID: 12901975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.